Biosimilars & “Pay-for-delay” Settlements

By: Samantha Schram   Competition in the pharmaceutical industry is fostered by the regulatory frameworks enacted to achieve a balance between innovation and consumer interests. In 1984, Congress enacted the Hatch-Waxman Act in an effort to address the growing cost of health care, as well as the necessity of continued medical innovation.[2]  The Hatch-Waxman Act […]